Recro Pharma Inc. (REPH) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Recro Pharma Inc.

    NASDAQ: REPH · Real-Time Price · USD
    2.09
    -0.01 (-0.48%)
    At close: Mar 22, 2022, 5:00 AM

    Recro Pharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 94.64M 90.21M 75.36M
    Cost of Revenue
    		 76.5M 67.08M 55.54M
    Gross Profit
    		 18.14M 23.14M 19.82M
    Operating Income
    		 -3.57M -32.84M 3.76M
    Interest Income
    		 394K n/a n/a
    Pretax Income
    		 -13.14M -18.78M -11.37M
    Net Income
    		 -13.27M -19.88M -26.5M
    Selling & General & Admin
    		 21.02M 21.95M 18.37M
    Research & Development
    		 n/a n/a n/a
    Other Expenses
    		 687K 67.98M 1.04M
    Operating Expenses
    		 21.71M 89.94M 19.41M
    Interest Expense
    		 -9.96M -14.06M 15.13M
    Selling & Marketing Expenses
    		 n/a n/a n/a
    Cost & Expenses
    		 98.21M 157.01M 74.95M
    Income Tax Expense
    		 132K 1.1M 15.13M
    Shares Outstanding (Basic)
    		 95.23M 57.88M 51.42M
    Shares Outstanding (Diluted)
    		 95.23M 57.88M 51.42M
    EPS (Basic)
    		 -0.14 -0.34 -0.52
    EPS (Diluted)
    		 -0.14 -0.34 -0.52
    EBITDA
    		 -3.57M 279K 11.33M
    EBIT
    		 -23.11M -32.84M 3.76M
    Depreciation & Amortization
    		 8.91M 33.11M 7.57M

    Add to Watchlist